Furthermore, CTLA4 is suggested to be an important checkpoint in the development of active MS lesions, as administration of CTLA4 blocking antibodies for treatment of melanoma in an MS patient was linked to the development of MS clinical symptoms and an increase in gadolinium enhancement of MS lesions on MRI 30. This evidence concerns the gene CTLA4 and myeloid sarcoma.